Biotech Catalysts This Week: 4 Trial Completions and 9 New Financings (Oct 18-25, 2026)

· 6 min read

This week brings no FDA decision dates, but four trial primary completions are estimated, including two povorcitinib studies in prurigo nodularis from INCY and a cutaneous lupus erythematosus study of litifilimab from BIIB. Last week saw two FDA approvals, for IRD and IBRX, alongside eight new company-guided timelines and twelve key SEC filings, with no delays or discontinuations recorded.

At a glance: this week no FDA decision dates, 4 Phase 2 or 3 trials reaching primary completion and 9 new financing filings. Last week: 2 FDA decisions, 8 new timelines announced and 12 key SEC filings.

🔄 What Changed Last Week

New timelines announced in press releases:

  • TLSA, intranasal foralum: Q1 2027. “Topline data are anticipated to be announced in Q1 2027.” SEC filing
  • EPRX, RESOLVE: December 2026. “The interim data from the Phase 2b portion of the RESOLVE trial are expected in December 2026.” SEC filing
  • CBIO, CR-001 (SKB118) and sac-TMT: mid-2027. “A Phase 2 trial of CR-001 (SKB118) and sac-TMT in participants with locally advanced or metastatic NSCLC is ongoing with initial data expected in mid-2027;” SEC filing
  • ONCY, pelareorep: fourth quarter of 2026. “Oncolytics expects to report final results from Cohort 4 in the fourth quarter of 2026.” SEC filing
  • CRVO, nfvPPA: in October 2026. “CervoMed reported initial 12-week biomarker data from its ongoing Phase 2a clinical trial in nfvPPA in October 2026 and expects to present 24-week biomarker data at CTAD in…” SEC filing
  • TCRT, VLR199: in 2028. “We believe this transaction and the concurrent private placement provide a strong financial foundation for us to advance an exciting pipeline and offer our stockholders a…” SEC filing
  • ZBIO, SunStone: in 4Q 2026. “Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE) topline results expected in 4Q 2026.” SEC filing
  • AQST, Anaphylm: in Q4 2026. “In parallel, we are advancing our commercial preparations so that we are ready for the potential launch of Anaphylm, if approved.” Aquestive continues to advance its ex-U.S.…” SEC filing

FDA decisions:

  • IRD Phentolamine Ophthalmic Solution 0.75%: approved (2026-10-17)
  • IBRX ANKTIVA: approved (2026-10-14)

Trial status changes on ClinicalTrials.gov:

  • IVVD: Phase 3 trial marked completed (2026-10-15). Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadminis Registry

📄 Key SEC Filings Last Week

Filings that can move a stock, each summarized from the filing itself; financing filings are under Dilution Watch below:

  • KRYS, 2026-10-15 (clinical trial): Reported early proof-of-concept data for KB113 in three Gorlin syndrome patients: over 80% of assessed basal cell carcinoma lesions regressed (69 of 83), including non-injected lesions. Company is discussing advanced development with the FDA. SEC filing
  • EPRX, 2026-10-15 (clinical trial): Reached its 120-patient enrollment target on October 12, 2026 in the placebo-controlled Phase 2b portion of the RESOLVE trial of EP-104GI for eosinophilic esophagitis. Over 3,000 injections given with no treatment-related serious adverse events; interim Phase 2b analysis expected December 2026. SEC filing
  • PHAR, 2026-10-14 (clinical trial): Pharming reported positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation, presented at ESID 2026. The filing references a press release for details and figures. SEC filing
  • ONCY, 2026-10-14 (clinical trial): Expects a final grant payment from the Pancreatic Cancer Action Network this quarter as GOBLET enrollment winds down. Final Cohort 4 results are expected in Q4 2026 and initial Cohort 5 results in the first half of 2027. SEC filing
  • COYA, 2026-10-14 (clinical trial): Coya plans an open-label extension of its ALSTARS Phase 2/3 trial of COYA 302 in ALS, starting November 2026, and has delayed the planned FTD Phase 2 trial start from the second half of 2026 to 2027. Cash runway into the second half of 2027 is unchanged. SEC filing
  • ASND, 2026-10-16 (regulatory): CHMP adopted a positive opinion recommending EU marketing authorization for once-weekly TransCon CNP (navepegritide) for achondroplasia in children two years and older with open epiphyses. The final European Commission decision is expected in Q4 2026, with a first EU launch as YUVIWEL in Germany planned for Q1 2027. SEC filing
  • LEGN, 2026-10-15 (regulatory): Legend Biotech said the FDA cleared its IND application for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T therapy for relapsed or refractory B-cell malignancies. The company plans a U.S. Phase 1/2 study. SEC filing
  • AVXL, 2026-10-15 (regulatory): FDA cleared Anavex’s IND for blarcamesine in Fragile X syndrome, allowing a planned Phase 2a study of about 60 adult males. Blarcamesine has Orphan Drug Designation for this indication, and no FDA-approved treatment exists. SEC filing
  • MEDS, 2026-10-16 (deal): DataMeds signed an exclusive US license with REBOOT Health AI for GLP-1 direct-to-consumer use, issuing 666,667 shares plus a $50,000 payment and revenue sharing. Nasdaq flagged stockholders’ equity of $(12,447,801) and the company is converting debt into stock. SEC filing
  • SNTI, 2026-10-15 (deal): Shareholders reconvened the 2026 annual meeting and approved the Merger Agreement with ST NewCo Limited, a reverse stock split of 1-for-20 to 1-for-50 at the Board’s discretion, and Nasdaq 5635(d) approval for issuance above 19.99% upon exchange of Midco notes. SEC filing
  • OCGN, 2026-10-15 (deal): Ocugen signed an exclusive license with Roots Pharmaceutical for OCU400, its retinitis pigmentosa gene therapy, in the Middle East and North Africa. Ocugen gets up to $4 million in upfront and development payments, up to $255.0 million in sales milestones, and 22% royalties on net sales. SEC filing
  • MBIO, 2026-10-15 (listing): Nasdaq granted Mustang Bio an additional 180-day period, until April 12, 2027, to regain compliance with the $1.00 minimum bid price requirement. The company may effect a reverse stock split if necessary. SEC filing

🧪 Phase 2 and 3 Trials Reaching Primary Completion

Estimated primary completion dates from ClinicalTrials.gov: the last patient reaches the main endpoint. Topline results usually follow weeks or months later.

  • INCY, 2026-10-19 (Phase 3): A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) Registry
  • INCY, 2026-10-19 (Phase 3): A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) Registry
  • BIIB, 2026-10-20 (Phase 2/3): A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus Registry
  • AZN, 2026-10-23 (Phase 2): This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight Registry

📡 Run-up Radar Highlights

Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):

  • ZURA: Phase 2 primary completion in 14 days, score 79/100
  • VSTM: Data readout guided for October 2026, window closes in 13 days, score 74/100
  • IMUX: Phase 3 primary completion in 14 days, score 72/100

💸 Dilution Watch: New Financing Filings

  • MEDS: private placement (8-K, 2026-10-16) EDGAR
  • MAZE: private placement (8-K, 2026-10-16) EDGAR
  • ALEC: ATM program up to $125M (424B5, 2026-10-16) EDGAR
  • ALXO: private placement (8-K, 2026-10-15) EDGAR
  • SILO: private placement (8-K, 2026-10-14) EDGAR
  • TCRT: private placement (8-K, 2026-10-13) EDGAR
  • HLSQ: private placement (8-K, 2026-10-13) EDGAR
  • CDT: private placement (8-K, 2026-10-13) EDGAR
  • ADCT: private placement (8-K, 2026-10-13) EDGAR

Full Dilution Watch table →

📉 Downside Radar: Trading Far Below a Recent Offering

Of biotech stocks 25% or more below their close on the day of a recent offering, 76% were lower 60 trading days later, median -29% (any biotech on a random day: 53% lower, median -2%). On the radar now:

  • DCOY: $1.17, 70% below $3.85, its close on the day of its Sep 23 private placement (new this week)
  • MDCX: $3.25, 60% below $8.15, its close on the day of its Sep 11 private placement (new this week)
  • LEXX: $2.86, 57% below $6.60, its close on the day of its Sep 9 private placement (new this week)
  • BKHA: $6.01, 51% below $12.19, its close on the day of its Sep 24 private placement (new this week)
  • GRML: $6.00, 49% below $11.85, its close on the day of its Sep 28 registered direct offering (new this week)
  • JUNS: $2.90, 49% below $5.66, its close on the day of its Aug 24 private placement (new this week)
  • KZIA: $7.25, 47% below $13.77, its close on the day of its Aug 31 underwritten offering (new this week)
  • JAGX: $3.52, 41% below $6.02, its close on the day of its Sep 28 private placement (new this week)

Full Downside Radar and how it was tested →

📈 Last Week’s Biggest Gainers

  • ESLA +68.35% (volume 45.9x average)
  • MXCT +29.63% (volume 16.2x average)
  • INDP +28.96% (volume 1.5x average)
  • LQDA +26.59% (volume 7.1x average)
  • HUMA +24.12% (volume 3.1x average)

Earlier weekly catalyst recaps →

Track your tickers on the BioRadar dashboard →

This digest is for informational purposes only and is not investment advice. Always do your own research.

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.